1-3 of 3
Filippo Spriano
Close
Sort by
Journal Articles

Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors

Afua Adjeiwaa Mensah, Filippo Spriano, Giulio Sartori, Valdemar Priebe, Luciano Cascione, Eugenio Gaudio, Chiara Tarantelli, Elisa Civanelli, Luca Aresu, Andrea Rinaldi, Giovanna Damia, Emanuela Lovati, Emanuele Zucca, Anastasios Stathis, Claudio Pietra, Francesco Bertoni
Journal: Blood Advances
Blood Adv (2021) 5 (10): 2467–2480.
https://doi.org/10.1182/bloodadvances.2020003566
Published: 2021
Includes: Supplemental data
Journal Articles

Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734

Filippo Spriano, Eugenio Gaudio, Luciano Cascione, Chiara Tarantelli, Federica Melle, Giovanna Motta, Valdemar Priebe, Andrea Rinaldi, Gaetanina Golino, Afua Adjeiwaa Mensah, Luca Aresu, Emanuele Zucca, Stefano Pileri, Michael Witcher, Bill Brown, Claes Wahlestedt, Francis Giles, Anastasios Stathis, Francesco Bertoni
Journal: Blood Advances
Blood Adv (2020) 4 (17): 4124–4135.
https://doi.org/10.1182/bloodadvances.2020001879
Published: 2020
Includes: Supplemental data
Journal Articles

Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models

Chiara Tarantelli, Martin Lange, Eugenio Gaudio, Luciano Cascione, Filippo Spriano, Ivo Kwee, Alberto J. Arribas, Andrea Rinaldi, Thibaud Jourdan, Melanie Berthold, Andrea Sturz, Carolyn Sperl, Francesco Margheriti, Lorenzo Scalise, Giuseppe Gritti, Davide Rossi, Anastasios Stathis, Ningshu Liu, Emanuele Zucca, Oliver Politz, Francesco Bertoni
Journal: Blood Advances
Blood Adv (2020) 4 (5): 819–829.
https://doi.org/10.1182/bloodadvances.2019000844
Published: 2020
Includes: Supplemental data